TORONTO, ON / ACCESSWIRE / September 29, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF) is a clinical stage pharmaceutical company that is dedicated to the research and development of light and radiation activated Photo Dynamic Compounds ("PDCs"), their associated drug formulations and the light systems that activate them. These PDCs are intended to safely and effectively destroy various cancers, bacteria and viruses, when light or radiation activated.

Supported by current Good Manufacturing Practice ("cGMP") analysis conducted by an independent manufacturing and testing laboratory, Theralase® announced that it has successfully demonstrated an 8 year, real-time, shelf life of its lead PDC, Ruvidar^TM.

Dr. Arkady Mandel, MD, PhD, DSc, Chief Scientific Officer of Theralase® stated, "Theralase®'s ability to demonstrate such an extended shelf life of its lead PDC, Ruvidar^TM is extremely encouraging, as it supports our ongoing clinical development plans. This independent analysis confirms the ability of Ruvidar^TM to be an extremely stable small molecule that has the ability to maintain its potency and purity over 8 years without significant degradation. This will allow our clinical partners to procure and store our PDC technology over many years without loss of clinical performance, minimizing the requirement to dispose of / replace unused drug over time."

Mr. Roger DuMoulin-White, BSc, P.Eng, Pro.Dir, President and Chief Executive Officer of Theralase® stated, "Since 2015, Theralase® has utilized the services of an external, independent testing laboratory to conduct accelerated aging and real time stability studies in the storage of Ruvidar^TM, with the goal of validating product purity and hence efficacy over time. The recent stability report validates the storage of Ruvidar^TM over 8 years, providing Theralase® additional support that it's lead drug can be successfully manufactured and sterilized, then subsequently stored at clinical study sites around the globe for many years. This extended shelf life allows our future commercial partners to be confident in the ability to procure and store our lead drug without risk of degradation of clinical performance over time. This will significantly reduce the cost of replacement of the drug due to spoilage / lack of efficacy. As a result of the latest report, Theralase® will continue to leverage our expertise in the research and development of new PDC formulations, such as Rutherrin®, to allow our anti-cancer technology to be available for additional cancer indications."

About Theralase® Technologies Inc.:

Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light and radiation activated compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses.

Additional information is available at www.theralase.com and www.sedar.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

This news release contains Forward-Looking Statements ("FLS") within the meaning of applicable Canadian securities laws. Such statements include, but are not limited to, statements regarding the Company's proposed development plans with respect to Photo Dynamic Compounds ("PDCs") and their drug formulations. FLS may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of the Company's management for future research, development and commercialization of the Company's PDCs and their drug formulations; including: preclinical research, clinical studies and development and regulatory approvals.

These statements involve significant risks, uncertainties and assumptions; including, whether the Company is able to: adequately fund and secure the requisite regulatory approvals to successfully complete preclinical and clinical studies in a timely fashion to implement its development plan; successfully commercialize its drug formulations; access sufficient capital to fund the Company's operations, which may not be available on terms that are commercially favorable to the Company or at all; provide preclinical and clinical support that the Company's drug formulations are effective against the conditions tested in its preclinical and clinical studies; comply with the term of license agreements with third parties, not to lose the right to use key intellectual property in its business; protect its intellectual property and the timing and success of this intellectual property and achieve acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.

Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will successfully come to fruition, and as such, FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS.

Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS.

All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements.

For More Information:
1.866.THE.LASE (843.5273)
416.699.LASE (5273)
www.theralase.com

Kristina Hachey, CPA
Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
416.699.LASE (5273) x 224